Divis Laboratories Ltd Share Price Today - Divis Laboratories Ltd Stock Price Live NSE/BSE

Divis Laboratories Ltd

NSE: DIVISLAB BSE: 532488

₹6352.50

(-0.31%)

Fri, 20 Mar 2026, 11:25 am

MTF 5xInvest in Divis Laboratories Ltd with 5x Leverage Buy with MTF

Market Cap1691.39B

PE Ratio68.03

Dividend0.47

Health Technology

Pharmaceuticals: Major

24.5K

Divis Laboratories Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

Market Cap
158686.50
Net Profit
2191
P/B
10.22
Sector P/E
32.08
P/E
69.82
EV/EBITDA
44.95
Debt/Equity (Industry)
0.16
Interest Cover (Industry)
20.07
ROCE (Industry)
20.49
RONW (Industry)
17.59
ROE
15.35
ROCE
20.42
Debt/Equity
0
EPS (TTM)
95.43
Dividend Yield
0.50
Book Value
580.60
Interest Cover
973

Analysis

all

Pros

Dividends per share have increased over the past 10 years.
Dividends paid are well covered by earnings (3.2x coverage).
Dividends after 3 years are expected to be well covered by earnings (3.1x coverage).
Dividends per share have been stable in the past 10 years.
Divi's Laboratories's earnings growth is expected to exceed the India market average.

Cons

Divi's Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
Divi's Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
Cash flow for Divi's Laboratories is expected to increase but not above the 50% threshold in 2 years time.
Divi's Laboratories's earnings are expected to grow by 18.9% yearly, however this is not considered high growth (20% yearly).
Divi's Laboratories's net income is expected to increase but not above the 50% threshold in 2 years time.

Financials

Ratios

Shareholders	DEC 2025	SEPT 2025	JUN 2025	MAR 2025	DEC 2024
Promoters	51.88	51.89	51.89	51.89	51.89
FII	20.08	19.39	19.74	18.01	17.99
DII	19.28	19.76	19.05	20.71	20.54
Public	8.76	8.96	9.32	9.39	9.58
Government	0.00	0.00	0.00	0.00	0.00

Technical Analysis

RSI

43.80

MACD

-48.46

50 DMA

6220.11

200 DMA

6368.50

Support and Resistance

Type	R3	R2	R1	PP	S1	S2	S3
Classic	8169.83	7266.83	6837.67	6363.83	5934.67	5460.83	4557.83
Fibonacci	7266.83	6921.89	6708.78	6363.83	6018.89	5805.78	5460.83
Camarilla	6656.82	6574.05	6491.27	6363.83	6325.73	6242.95	6160.18

Pivots Level: Classic

+1806

8169.83

+903

7266.83

+473.83

6837.67

6363.83

Pivot Point

LTP: 6100

-429.17

5934.67

-903

5460.83

-1806

4557.83

Moving Average

SMAEMA

Period

Value

10-EMA
6150.24
20-EMA
6202.23
30-EMA
6221.35
50-EMA
6246.72
100-EMA
6281.09
200-EMA
6231.31

Announcement Date	Purpose	Action	Ex Date
11 Feb 2026	board-meetings	Quarterly Results, Nine Months Results
07 Nov 2025	board-meetings	Quarterly Results
25 Jun 2025	dividend	Final Dividend - Rs. - 30	25 Jul 2025
17 May 2025	dividend	₹30.00 Dividend /Share	25 Jul 2025
17 May 2025	agm
02 Jul 2024	dividend	Final Dividend - Rs. - 30	02 Aug 2024
25 May 2024	dividend	₹30.00 Dividend /Share	02 Aug 2024
25 May 2024	agm
11 Jul 2023	dividend	Final Dividend - Rs. - 30	11 Aug 2023
03 Jul 2023	agm

Divis Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd

Lupin Ltd

Cipla Ltd

Divis Laboratories Ltd About

Divis Laboratories is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports.

Industry

Pharmaceuticals - Indian - Bulk Drugs

Founded

1990

Headquarters

CEO

Ramesh B V Nimmagadda

Employees

Contact

Website

http://www.divislabs.com

mail@divislaboratories.com; cs@divislaboratories.c

Phone

91-40-23786300/23786352/400

Location

1-72-23(P)/DIVIS/303 Divi Towe, Cyber Hills Gachibowli, Hyderabad, Telangana, 500032

Year	History
2019	Divi's Laboratories approved an additional investment of $250M towards expansion of production blocks in Unit-I and Unit-II. The 7th USFDA inspection in Unit 2 took place.
2020	Commissioning of new production blocks in DC SEZ at Unit-I and DCV SEZ at Unit-II occurred. US-FDA inspection of Unit-II at Village Chippada, Andhra Pradesh took place. Commencement of commercial production from DCV-SEZ Unit began. Construction of Divi's Laboratories Unit-III Facility near Kakinada commenced.
2021	Ground breaking of the manufacturing plant in Kakinada took place.
2022	Divi's Laboratories received the EHS excellence Award. Divi's Laboratories reached the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad.
2024	Divi's Laboratories has a global presence in supplying APIs to more than 100 countries.

Client Name	Order Side	QTY	Avg Price	Date
INTEGRATED CORE STRATEGIES (ASIA) PTE.LTD.	Sell	1886001	1438.98	30 Nov 2018
BLACKROCK INDIA EQUITIES FUND (MAURITIUS) LIMITED	Sell	1454375	1047.17	31 May 2018
INTEGRATED CORE STRATEGIES (ASIA) PTE.LTD.	Buy	2285198	582.12	31 May 2017
BARCLAYS GLOBAL FUND ADVISORS A/C ISHARES INDIA MAURITIUS C	Sell	2373622	582.9	31 May 2017
VANGUARD EMERGING MARKETS STOCK INDEX FUND A SERIES OF VANG	Buy	955020	1194.11	30 Nov 2012
VANGUARD EMERGING MARKETS STOCK INDEX FUND A SERIES OF VANG	Buy	955020	1194.11	30 Nov 2012
DEUTSCHE SECURITIES MAURITIUS LIMITED	Buy	2160000	1397	24 Sept 2008
MERRILL LYNCH CAPITAL MARKETS ESPANA S.A. SVB	Sell	2160000	1397	24 Sept 2008
MERRILL LYNCH CAPITAL MARKETS ESPANA S.A. S.V.	Buy	67649	3939.93	22 May 2007
GOLDMAN SACHS AND CO SUB	Sell	75000	1260.04	18 Jul 2006

Divis Laboratories Ltd News

Divi's Labs Board Meet on Feb 11 for Q3FY26 Results

Divi's Laboratories has scheduled a board meeting on February 11, 2026, to consider and approve Q3FY26 financial results. Trading window remains closed until February 13, 2026.

30 Jan 2026

co actions results

Divis Labs Dec Exports Surge 49% MoM to $117m

Divis Laboratories reported strong December export performance with $117 million in shipments, marking a significant 49% month-on-month growth and demonstrating robust international demand.

13 Jan 2026

stocks

Divi's Labs Sees ₹66.53 Cr NSE Block Trade

Divi's Laboratories witnessed a significant block trade on NSE worth ₹66.53 crores involving 103,549 shares at ₹6,424.50 per share, indicating substantial institutional activity in the pharmaceutical stock.

12 Jan 2026

co actions results

Morgan Stanley Sets Overweight Rating on Divi's Labs

Morgan Stanley maintains overweight rating on Divi's Laboratories with price target of ₹7,541.00, reflecting positive outlook on the pharmaceutical company's prospects.

22 Dec 2025

stocks

Divi's Labs Reports Strong Export Growth in December

Divi's Laboratories achieved remarkable 68% month-over-month and 17% year-over-year export growth in US dollar terms, demonstrating strong international market performance.

19 Dec 2025

co actions results

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800